WO2003041654A3 - Anti-estrogen and immune modulator combinations for treating breast cancer - Google Patents

Anti-estrogen and immune modulator combinations for treating breast cancer Download PDF

Info

Publication number
WO2003041654A3
WO2003041654A3 PCT/US2002/036633 US0236633W WO03041654A3 WO 2003041654 A3 WO2003041654 A3 WO 2003041654A3 US 0236633 W US0236633 W US 0236633W WO 03041654 A3 WO03041654 A3 WO 03041654A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune
estrogen
inhibitor
immune inhibitor
breast cancer
Prior art date
Application number
PCT/US2002/036633
Other languages
French (fr)
Other versions
WO2003041654A2 (en
Inventor
David A Sirbasku
Original Assignee
David A Sirbasku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David A Sirbasku filed Critical David A Sirbasku
Priority to EP02793936A priority Critical patent/EP1515748A4/en
Priority to AU2002359401A priority patent/AU2002359401A1/en
Publication of WO2003041654A2 publication Critical patent/WO2003041654A2/en
Publication of WO2003041654A3 publication Critical patent/WO2003041654A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions for treating cancers of mucosal tissues including breast, prostate, ovary, colon are disclosed which include various combinations of new or conventional anti-estrogen compounds, aromatase inhibitors, immune modulators, immune inhibitors, immune inhibitor mimicking compounds and steroid or thyroid hormones. Methods of predicting susceptibility of a cancer of mucosal origin to treatment with a composition containing an immune inhibitor or an immune inhibitor mimicking compound are also disclosed. Preferred methods include identifying in a specimen of cancer cells the presence of a Poly-Ig (Fc) receptor or Poly-Ig-like (Fc) receptor capable of binding to an immune inhibitor or an immune inhibitor mimicking compound and of mediating immune inhibition of cancer cell growth.
PCT/US2002/036633 2001-11-14 2002-11-13 Anti-estrogen and immune modulator combinations for treating breast cancer WO2003041654A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02793936A EP1515748A4 (en) 2001-11-14 2002-11-13 Anti-estrogen and immune modulator combinations for treating breast cancer
AU2002359401A AU2002359401A1 (en) 2001-11-14 2002-11-13 Anti-estrogen and immune modulator combinations for treating breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33280101P 2001-11-14 2001-11-14
US60/332,801 2001-11-14

Publications (2)

Publication Number Publication Date
WO2003041654A2 WO2003041654A2 (en) 2003-05-22
WO2003041654A3 true WO2003041654A3 (en) 2005-01-06

Family

ID=23299909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036633 WO2003041654A2 (en) 2001-11-14 2002-11-13 Anti-estrogen and immune modulator combinations for treating breast cancer

Country Status (3)

Country Link
EP (1) EP1515748A4 (en)
AU (1) AU2002359401A1 (en)
WO (1) WO2003041654A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505856A (en) * 2011-12-16 2015-02-26 オレマ ファーマシューティカルズ インク． Novel benzopyran compounds, their composition and use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261787B1 (en) * 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
WO2001086307A2 (en) * 2000-05-10 2001-11-15 Sirbasku David A Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (en) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre ANTI-ESTROGEN MEDICINAL PRODUCT BASED ON 4-HYDROXYTAMOXIFENE FOR PERCUTANEOUS ADMINISTRATION
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261787B1 (en) * 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
WO2001086307A2 (en) * 2000-05-10 2001-11-15 Sirbasku David A Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1515748A4 *

Also Published As

Publication number Publication date
WO2003041654A2 (en) 2003-05-22
AU2002359401A1 (en) 2003-05-26
EP1515748A2 (en) 2005-03-23
EP1515748A4 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
NO961706D0 (en) Composition that binds particularly to colorectal cancer cells, as well as to the method of using the same
MY141605A (en) Method of treating certain cancers using an estrogen agonist/antagonist
AU9263101A (en) Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
DE60011755D1 (en) Calcium channel blocker as anti-cancer agent
AU2003264068A1 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
MXPA01003344A (en) Compositions and methods for wt1 specific immunotherapy.
ATE294595T1 (en) RADIOACTIVE COMPOSITIONS FOR TREATING PROSTATE TUMORS
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
GEP20074209B (en) Multi-substitued selective androgen receptor modulators and methods of use thereof
AU3752700A (en) Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
MXPA01008137A (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase.
WO2001019956A3 (en) A method for isolation of prostatic epithelial cells from semen
HK1071697A1 (en) Inhibition of the growth factor dependency of tumor cells
AU7701100A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
GB2378948B (en) Novel compounds for modulating cell proliferation
WO2003041654A3 (en) Anti-estrogen and immune modulator combinations for treating breast cancer
AU2002341749A1 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
MXPA05006507A (en) Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor.
YU30003A (en) Inhibition of the growth factor dependency of tumor cells
WO2005040347A3 (en) Methods and compositions for inhibiting cell growth and proliferation
NZ335903A (en) Anti-proliferative radiolabelled DNA oligonucleotide, preparation and use for controlling uncontrolled cell proliferation
BR0212641A (en) Method for antigen identification, method for producing a compound, method for inhibiting cell proliferation, method for treating cancer, composition and use
AU2001238499A1 (en) Nitroacridine/tumor inhibitor compositions
MXPA01003636A (en) Methods and compositions for inhibiting neoplastic cell growth.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002793936

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002793936

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP